Aclaris Therapeutics, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ACRS, updated each market day.
ACRS AI Sentiment
AI sees no strong directional signal for Aclaris Therapeutics, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Sector
Exchange
Market Cap
$494,035,975
Cap Tier
Employees
73
Headquarters
WAYNE, PA
Listed Since
Oct. 7, 2015
Website
ACRS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ACRS Volatility
Aclaris Therapeutics, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
